南华生物(000504) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥19,781,947.78, an increase of 480.01% year-on-year, while year-to-date revenue reached ¥55,784,999.43, up 216.87% compared to the same period last year[8] - Net profit attributable to shareholders of the listed company was -¥7,560,178.38, a decrease of 10.58% year-on-year, with year-to-date net profit at -¥23,010,118.49, down 12.29%[8] - Basic earnings per share for the reporting period were -¥0.0243, a decrease of 10.33% year-on-year, while diluted earnings per share were also -¥0.0243[8] - The weighted average return on equity was -139.71%, compared to -281.66% in the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥385,907,384.51, a decrease of 4.66% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company were ¥1,763,276.95, down 92.84% from the previous year-end[8] - Cash and cash equivalents decreased by 60.42% to ¥65,937,508.89 due to payments for subsidiary acquisitions and repayment of bank and shareholder loans[16] - Accounts receivable increased by 173.89% to ¥14,285,599.47, attributed to new accounts from subsidiaries Yuantai Bio and Aishipulin[16] - Inventory rose by 46.15% to ¥36,220,559.77, driven by increases from subsidiaries Yuantai Bio and Aishipulin[16] Operating Activities - The net cash flow from operating activities was -¥18,597,774.58, a decrease of 63.36% year-on-year[8] - Cash received from operating activities increased by 52.77% to ¥80,478,899.29, reflecting higher sales from the newly acquired subsidiary Yuantai Bio[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,311[12] - The largest shareholder, Hunan Trust Co., Ltd., held 25.58% of the shares, amounting to 79,701,655 shares[12] Expenses - Sales expenses increased by 389.90% to ¥12,172,774.42, reflecting higher costs from subsidiaries Yuantai Bio and Aishipulin[17] - R&D expenses grew by 207.04% to ¥5,836,478.18, mainly due to increased spending from subsidiary Yuantai Bio[17] - The company reported a 6044.35% increase in other operating expenses to ¥1,497,679.08, due to the establishment of a non-profit organization[17] Investments - The company reported a total investment in securities amounting to 2,190.44 million yuan, with a fair value change of -713,209.95 yuan[20] - The company has invested 6,110 million yuan in bank wealth management products, with an unexpired balance of 4,050 million yuan[23] Financial Management - There were no overdue amounts or expected losses on the principal for the entrusted financial management[23] - The company did not engage in any derivative investments during the reporting period[24] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[26]